All In Biotech

Drug Trial Radar · NCT00467870

Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men

A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men

Last checked: Nov 19, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 531 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

531

Actual

Start

Mar 2006

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Sponsor type
Industry
First posted
May 1, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the pharmacokinetics of TU 750 mg and TU 1000 mg via multiple measurements of serum total testosterone.

Conditions

  • Hypogonadism
  • Primary Hypogonadism
  • Secondary Hypogonadism

Interventions

  • Testosterone Undecanoate 750 mgDrug

  • Testosterone Undecanoate 1000 mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14
  2. Serum Total Testosterone Average Concentration During the 3rd Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14
  3. Serum Total Testosterone Maximum Concentration During the 3rd Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14
  4. Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 3rd Injection in Part CTime frame: Day 70 post injection at week 14
  5. Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 4th Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 42, and 70 post injection at week 24
  6. Serum Total Testosterone Average Concentration During the 4th Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 42, and 70 post injection at week 24
  7. Serum Total Testosterone Maximum Concentration During the 4th Injection Interval in Part CTime frame: Days 0, 4, 7, 11, 42, and 70 post injection at week 24
  8. Serum Total Testosterone Concentration at the End of the Dosing Interval Following the 4th Injection in Part CTime frame: Day 70 post injection at week 24
  9. Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration Criteria for Success During the 2nd Injection Interval in Part C2Time frame: Days 0, 4, 7, 11, 14, and 70 post injection at week 4
  10. Serum Total Testosterone Average Concentration During the 2nd Injection Interval in Part C2Time frame: Days 0, 4, 7, 11, 14, and 70 post injection at week 4
  11. Serum Total Testosterone Maximum Concentration During the 2nd Injection Interval in Part C2Time frame: Days 0, 4, 7, 11, 14, and 70 post injection at week 4
  12. Serum Total Testosterone at the End of the Dosing Interval Following the 2nd Injection in Part C2Time frame: Day 70 post injection at week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Indevus Pharmaceuticals, Inc.

    Lexington, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.